Alembic Pharmaceuticals Limited has informed the stock exchanges that the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Betamethasone Valerate Foam, 0.12%. This approval marks a pivotal step for Alembic Pharmaceuticals, as the product is therapeutically equivalent to Luxiq Foam, 0.12%, developed by …


